EDMONTON, Alberta, March 16 /PRNewswire-FirstCall/ -- Medical Services International Inc., (OTC:MSITF) wishes to announce that the Company has been asked to supply the VScan Dengue Fever Kit to several countries in the Middle East. Over the last month there has been a serious outbreak of Dengue Fever in the Middle East and it is very difficult to get testing done in standard labs. Further, the delay of results is up to three weeks even if there is space at the lab. Dengue Fever is transmitted by mosquitos. In order to control the out break on Dengue Fever there must be access to fast accurate testing. The Vscan Dengue Fever Kit gives fast accurate testing. The VScan Dengue Fever kits is a dual flow kit that detects both IgM and IgG individually and at the same time. Any other Dengue kit currently on the market only detects IgG and as such is not as sensitive and accurate as the VScan test kit. The key to treating and controlling outbreaks of Dengue Fever is fast, accurate testing. The VScan Dengue Fever test kit is an accurate (greater than 99% of the time) easy to use test kit that gives results in under 15 minutes. The treatment for certain kinds of Dengue Fever is fluid replacement therapy that is only effective if administered quickly after infection. Based on conversations with our distributor in the area, there will be requirements for at least 500,000 Dengue Test kits this year in the Middle East. The first Dengue Fever kits to the Middle East have already been shipped. About VScan The VScan rapid test kit is a single use, disposable, accurate, cost effective, easy to use test for the screening of HIV1&2, Hepatitis B&C, Tuberculosis (TB), Dengue Fever, West Nile, Syphilis, Malaria and Prostate Cancer. The kits cannot be sold in Canada. Medical Services International Inc. trades in the Unites States on the NQB Pinksheets under the symbol "MSITF". For further information, please contact Robert Talbot at (780) 430 6363 or http://www.medicalservicesintl.com/ or http://www.minerva-biotech.com/ . NOTE: Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause results to differ materially. Such risks, uncertainties and other factors include but are not limited to new economic conditions, risk in product development, market acceptance of new products and continuing product demand, level of competition and other factors described in Company reports and other filings with regulatory bodies. Medical Services International Inc. DATASOURCE: Medical Services International Inc. CONTACT: Robert Talbot of Medical Services International Inc., +1-780-430-6363 Web site: http://www.medicalservicesintl.com/ http://www.minerva-biotech.com/

Copyright